SCHEMBL1044907

SCHEMBL1044907

Cc1ccc(-c2c(F)cccc2F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.52
ACHE P22303 4/20 0.43
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
DHODH Q02127 1/20 0.41
NFE2L2 Q16236 1/20 0.41
MEN1 O00255 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
KMT2A Q03164 1/20 0.41
RELA Q04206 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
PTGS2 P35354 3/20 0.40
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919253 0.85 TTR (0.40) TTRACHEGAASMN1; SMN2ALDH1A1
SCHEMBL4910768 0.85 ADORA2A (0.41) TTRACHEGAASMN1; SMN2NPC1
SCHEMBL29000156 0.83 ACHE (0.43) TTRACHEGAASMN1; SMN2ALDH1A1
SCHEMBL10018706 0.80 ACHE (0.43) ACHEDHODHNFE2L2TDP1PTGS2
SCHEMBL13615034 0.79 TTR (0.56) TTRACHEALDH1A1NPC1RAB9A
SCHEMBL593550 0.79 TTR (0.56) TTRGAASMN1; SMN2ALDH1A1NPC1
SCHEMBL1043323 0.78 ACHE (0.48) ACHESMN1; SMN2NFE2L2MEN1KMT2A
SCHEMBL13761289 0.78 PTGS2 (0.54) ACHENFE2L2TDP1PTGS2PTGS1
SCHEMBL17943190 0.78 NFE2L2 (0.42) ACHEDHODHNFE2L2TDP1PTGS2
SCHEMBL17942997 0.78 ACHE (0.42) ACHEALDH1A1DHODHNFE2L2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2015-08-13 US disclosed
US-8987304-B2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
US-8952207-B2 Copper-catalyzed C—H bond arylation THE UNIVERSITY OF HOUSTON SYSTEM (US) 2015-02-10 US disclosed
EP-2269694-A2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-01-05 EP disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-11-05 US disclosed
US-20090076266-A1 COPPER-CATALYZED C-H BOND ARYLATION THE UNIVERSITY OF HOUSTON SYSTEM (US) 2009-03-19 US disclosed
WO-2008012413-A2 PYRIMIDINONE DERIVATIVES AND THEIR USE AS A DRUG SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TTR 2898/4885ACHE 2191/4885GAA 976/4885
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 TTR 296/4885ACHE 223/4885GAA 56/4885
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TTR 2898/4885ACHE 2191/4885GAA 976/4885
US-20090076266-A1 COPPER-CATALYZED C-H BOND ARYLATION AOC2, AOC3, DBH TTR 4008/4885ACHE 3552/4885GAA 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.